Original Article

The Effects of Arnigol Cream on Pain Associated with Arteriovenous Fistula Puncture in Patients Receiving Hemodialysis: A Randomized Double-Blind Clinical Trial study

Somayeh Nejadbagheri, Habibollahe S Hosseini¹, Majid Kazemi²

Department of Medical Surgical Nursing, School of Nursing and Midwifery, Rafsanjan University of Medical Sciences, Departmnet of Nursing, Nursing and Midwifery School, Geriatric Care Research Center, Rafsanjan University of Medical Sciences, Departmnet of Medical Surgical Nursing, Faculty of Nursing and Midwifery, Non-Communicable Disease Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

ORCID:
Somayeh Nejadbagheri: http://orcid.org/0000-0002-7144-9265; Habibollahe S Hosseini: http://orcid.org/0000-0001-6939-670X; Majid Kazemi: http://orcid.org/0000-0001-5623-6416

ABSTRACT

Background: In each hemodialysis session, hemodialysis patients undergo two vascular punctures with large-diameter needles, which are associated with great pain. The reduction of puncture pain helps these patients accept hemodialysis and enhances their quality of life. Objective: The present study was conducted to assess the effects of Arnigol cream on the pain associated with arteriovenous fistula puncture. Methods: As a double-blind single-group randomized clinical trial, the present study was made on 71 hemodialysis patients. Each patient received an arterial and a venous fistula puncture. One puncture site was randomly allocated to the experiment and the other one to the placebo. Before needle insertion, the experiment and the placebo sites were treated for 10 min with 5 ml of Arnigol cream or Vitamin A and D ointment, respectively. After needle insertion, pain intensity at puncture sites was assessed using a visual analog scale. The data were analyzed using the paired-sample t-test. Results: Participants were 71 hemodialysis patients, 49.3% were female. The mean of participants’ age was 56.8 ± 15.10 years, with a range of 22–82. The length of receiving hemodialysis ranged from 4 to 96 months with a mean of 40.36 ± 22.79. Diabetes mellitus was the major cause of renal failure among participants (56.3%). The intensity of pain at the experiment site was significantly lower than the placebo site (2.83 ± 1.60 vs. 3.46 ± 1.57; P = 0.006). Conclusions: This study showed the effectiveness of Arnigol cream in reducing the pain associated with arteriovenous fistula puncture among patients receiving hemodialysis. Thus, nurses are recommended to use this simple, safe, and inexpensive modality to reduce fistula puncture pain.

KEYWORDS: Arnigol, Hemodialysis, Fistula, Pain management, Puncture pain

INTRODUCTION

Chronic renal failure is a multifactorial physiopathologic problem which finally results in the reduction of the number and the function of nephrons.¹ Patients with chronic renal failure need treatments such as kidney transplantation, hemodialysis, or peritoneal dialysis.²,³ The most common treatment for the disease is hemodialysis.⁴ A prerequisite to regular long-term hemodialysis is permanent vascular access,⁵ which can be established through central venous catheter, arteriovenous graft, or arteriovenous fistula.⁶ The most preferred access route is arteriovenous fistula.⁷

Hemodialysis through arteriovenous fistula necessitates one arterial and one venous puncture using two large-diameter needles. Such punctures usually cause severe pain and discomfort for patients.⁷ Patients who receive regular hemodialysis are frequently exposed to the pain associated with around 300 vascular punctures.

Address for correspondence: Dr. Majid Kazemi, Department of Medical Surgical Nursing, Faculty of Nursing and Midwifery, Non-Communicable Disease Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. E-mail: maj_kaz@yahoo.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

each year.[8] Such repetitive exposure to pain causes anxiety and depression, reduces the quality of life,[7,9] and interferes with effective role performance.[10]

Pain is an unpleasant emotional and sensory experience due to an actual or potential tissue injury. It is among the most important nursing diagnoses, and its management is among the most important nursing responsibilities.[11] Effective pain management improves patient satisfaction with nursing care,[12] encourages patients to actively engage in the process of treatment,[13] helps them readily accept hemodialysis, and enhances their quality of life.[7] Thus, effective plans are needed to manage vascular puncture pain among hemodialysis patients.


Arnigol is an herbal cream (produced by Goldaru Co., Isfahan, Iran), each 100 mg of which contains 5 mg of Arnica montana extract. A. montana contains sesquiterpene lactones, polyynes, flavonoids, hydroxycumarines, and caffeic acid derivatives and has analgesic, anti-inflammatory, and antiseptic effects.[23] Thus, it is effective in managing skin wounds, particularly those with inflammation.[24] It has been reported to have no adverse effects. Clinical studies reported that Arnica-containing gels were effective in reducing muscular pain and improving venous tone.[23] However, it is unknown whether Arnigol cream is effective in reducing acute pain associated with arteriovenous fistula puncture.

Previous research studies introduced some pain-reducing methods. However, these methods are not routinely used by Iranian hemodialysis nurses due to their expensiveness, adverse effects, or difficulty of use. Despite the expensiveness and the safety of Arnigol cream, there are limited data about its effects on the pain associated with arteriovenous fistula puncture.

**Objectives**

The present study was conducted to assess the effects of Arnigol cream on the pain associated with arteriovenous fistula puncture.

**Methods**

**Design and participants**

This was a double-blind single-group randomized clinical trial. Each patient in the study was both the experimental and the placebo case. As pain is a subjective phenomenon, considering each patient as both the experimental and the placebo case could minimize the effects of intervening factors such as gender and age. Accordingly, one fistula puncture (either arterial or venous) was randomly regarded as the experiment and the other as the placebo.

This study was done from February to May 2016, in the hemodialysis units of Ali Ibn-e- Abi Talib (PBUH) Hospital, Rafsanjan, Iran, and Shafa hospital, Kerman, Iran. Population of the study consisted of all hemodialysis patients who had an arteriovenous fistula in their hand and received hemodialysis in the study setting. Patients were included if they were receiving hemodialysis through arteriovenous fistula at least two times a week for 3 consecutive months, were fully conscious, aged 18 or more, did not suffer from neuropathies or peripheral vascular problems, had no sign of inflammation at fistula site, received no topical analgesic at fistula site before the study intervention, and had no known allergy to Arnigol cream. Exclusion criteria were unsuccessful puncture at the first attempt and participants’ voluntary withdrawal from the study. Primarily, selected patients were tested for any allergy to Arnigol cream through applying 1 ml of the cream to a 5 cm surface area on their arms.

Sample size was calculated based on the results of an earlier study which reported two pain mean scores of 8.09 ± 1.92 and 10.11 ± 4.85.[7] Accordingly, with a type I error of 0.05 and a power of 0.90, the sample size calculation formula showed that 71 patients were needed for the study [Figure 1].

**Instruments and measurements**

Two instruments were used to collect data. The first instrument was a demographic and hemodialysis-related questionnaire which comprised of items such as age, gender, marital and educational status, cigarette smoking, drug abuse, underlying cause of renal failure, and history of receiving hemodialysis. The second instrument was a visual analog scale (VAS) for puncture pain assessment. VAS was a 10 cm ruler on which 0 and 10 represented “no pain” and “the severest experienced pain,” respectively.

\[
\begin{align*}
\frac{\sigma^2 + s^2}{(1.96 + 1.28)^2(1.92^2 + 4.85^2)(2.02)^2} &= 71 \\
\end{align*}
\]

**Figure 1:** Sample size calculation
Procedure
Arterial and venous punctures were performed on one hand of each patient with a 5 min interval. One site was randomly allocated to the experiment and the other to the placebo. Accordingly, for the first patient, arterial puncture was allocated to the experiment, and venous puncture was allocated to the placebo. For the second patient, this allocation was reversed. At the experiment site, 5 ml of Arnigol cream was applied 10 min before the puncture. The placebo site was similarly treated with 5 ml of Vitamin A and D mixture ointment. After 10 min of ointment application, the puncture sites were cleaned using antiseptic agents and then punctures were made. All participants were blind to the interventions, i.e., to the type of the cream used for them. The distance between the site of applying Arnigol cream and Vitamin A and D ointment was about 10 cm to prevent the effects of Arnigol cream on the placebo site. Moreover, the time interval between arterial and venous punctures was 5 min to remove the effects of the first puncture on the outcomes of the second. All punctures were performed by an experienced hemodialysis nurse, and then needles were fixated using hypoallergenic adhesive tape. Immediately after each puncture, the level of patient’s puncture pain was assessed and documented by another nurse using VAS. All punctures were performed similarly using 16-gauge needles and with a needle insertion degree of 30°-45°. Beside participants, the nurse who did pain assessments was also blind to the interventions.

Data analysis
The data were analyzed using the SPSS software version 13 (SPSS INC., Chicago, IL, USA). The distributions of the numerical variables were assessed through the Kolmogorov–Smirnov test, and all were normally distributed. Then, pain intensity comparisons were done using the paired sample t-test at a significance level of 0.05.

Ethical considerations
The ethical approval for this study was provided by the Ethics Committee of Rafsanjan University of Medical Sciences, Rafsanjan, Iran, with the code of IR.RUMS.REC.1394.166. In addition, the study was registered in the Iranian Registry of Clinical Trials with the code of IRCT2016112615965N8. The aim and the methods of the study were described to all participants, and their written informed consents were secured. They were ensured that participation in the study was voluntary. We also adhered to the ethical principles of medical research reported in the Declaration of Helsinki.

Results
Participants were 71 hemodialysis patients [Figure 2], 35 of them (49.3%) were female. The mean of participants’ age was 56.86 ± 15.10, with a range of 22–82. The length of receiving hemodialysis ranged from 4 to 96 months, with a mean of 40.36 ± 22.79. Diabetes mellitus was the major cause of renal failure [56.3%; Table 1].

The results of the paired-sample t-test illustrated that pain intensity at the experiment site was significantly lower than the placebo site (2.83 ± 1.60 vs. 3.46 ± 1.57; \( P = 0.006 \)). Comparison of pain intensity with respect to the history of diabetes mellitus indicated that Arnigol cream was more effective in reducing puncture pain among nondiabetic patients compared with diabetic ones (2.61 ± 1.35 vs. 3.48 ± 1.65; \( P = 0.008 \)). Moreover, patients who had received hemodialysis for more than 48 months experienced slighter pain compared with those who had a shorter history of hemodialysis \( [P = 0.005; \text{Table 2}.] \)

Discussion
The study was conducted on a single group of patients to remove the probable effects of intervening factors (such as age and gender). The findings indicated that the intensity of puncture pain at the Arnigol-treated puncture site was significantly lower than the site treated with Vitamin A and D ointment. Similarly, Jeffery and Belcher found that Arnica cream and tablet were more effective than a placebo in reducing pain after carpal tunnel release surgery.[20] The similarity between our findings and the findings reported by Jeffery and Belcher may be due to the similarity of the active ingredients of Arnica and Arnigol creams, i.e., sesquiterpenes...
The findings of this study suggest that Arnigol cream is effective in reducing the intensity of the pain associated with arteriovenous fistula puncture and thereby improving comfort among patients receiving hemodialysis. Thus, nurses are recommended to use this simple, safe, and inexpensive modality to reduce fistula puncture pain. Still, we recommend the future investigators to use more objective pain assessment methods to produce more conclusive evidence regarding the effects of Arnigol cream.

**Acknowledgment**

Hereby, we would like to thank the staffs of the dialysis units of Ali Ibn-e- Abi Tlib (PBUH) Hospital, Rafsanjan, Iran, and Shafa Hospital, Kerman, Iran, and the hemodialysis patients who participated in this study.

**Financial support and sponsorship**

This study was a piece of a master’s thesis in nursing and supported by Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

Nejadbagheri, et al.: Effects of arnigol cream on pain


